Calithera Biosciences Reports First Quarter 2015 Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Calithera Biosciences Reports First Quarter 2015 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., May 7, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA ), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, announced today its financial results for the first quarter ended March 31, 2015. As of March 31, 2015, cash, cash equivalents and investments totaled $94.3 million.

"During the first quarter, we continued to advance and expand our development pipeline," said Susan Molineaux, PhD, President and Chief Executive Officer of Calithera. "With the addition of the Hexokinase II license, we have expanded our portfolio of preclinical programs and continue to advance our expertise in the area of tumor metabolism drug research and development. At the 2015 American Association of Cancer Research annual meeting, we and our collaborators presented six abstracts highlighting synergy studies and potential biomarkers, which could ultimately direct the development of CB-839, our first in class glutaminase inhibitor. CB-839 is currently enrolling expansion cohorts in our Phase I clinical trials, and we look forward to updating you on our progress with CB-839 later in May."

First Quarter 2015 and Recent Highlights

  • Enrollment continues across CB-839 Phase Ib expansion cohorts. Updated data from the Phase I solid tumor trial has been accepted for presentation at the 2015 American Society of Clinical Oncology (ASCO) annual meeting on Saturday, May 30, 2015.
  • Hexokinase II inhibitors research license. In March 2015, Calithera gained exclusive worldwide rights to TransTech Pharma's portfolio of hexokinase II inhibitors. Hexokinase II is the first and rate-limiting enzyme in the pathway that enables cancer cells to convert glucose to energy and building blocks that feed cancer growth. It is the third program in Calithera's pipeline.
  • Preclinical findings, including biomarker data, presented at the American Association of Cancer Research. In April 2015, Calithera presented preclinical data that could ultimately direct the development of CB-839 in non-small cell lung cancer, renal cell carcinoma, and other solid tumor and hematologic indications. The presentations added KRAS and EGFR to our expanding list of potential biomarkers and reiterated data on preclinical single agent activity. Additionally, preclinical synergy studies with signal transduction inhibitors and other anti-cancer agents were also presented.

Selected First Quarter 2015 Financial Results

Research and development expenses were $5.6 million for the three months ended March 31, 2015, compared with $3.3 million for the same period in the prior year. The increase of $2.3 million was primarily attributed to higher expenses associated with the continued advancement of CB-839, investments in the Company's arginase inhibitor program, and a license fee associated with the hexokinase II program. In March 2015, Calithera gained exclusive rights to hexokinase II inhibitors from TransTech Pharma.

General and administrative expenses were $2.2 million for the three months ended March 31, 2015, compared with $0.8 million for the same period in the prior year. The increase of $1.4 million was primarily due to higher employment related expenses, including stock-based compensation expense, and professional service fees associated with operating as a publicly-traded company.

Net loss from operations for the three months ended March 31, 2015 was $7.9 million.

Financial Guidance for 2015

Calithera reiterates its guidance of its cash, cash equivalents and investments to be at least $65 million at the end of 2015, exclusive of any license milestone payments or funds arising from any additional new collaborations or partnerships, equity financings or other new sources.

Conference Call Information

Calithera will host its first quarter financial results and corporate update conference call today, May 7 th at 4:30 p.m. Eastern Time. The call can be accessed by dialing (855) 783-2599 (domestic) or (631) 485-4877 (international), and reference to conference ID 38836650. To access the live audio webcast or the subsequent archived recording, visit the Investors section of the Calithera website at www.calithera.com . The webcast will be recorded and available for replay until the Company's conference call to discuss financial results for its second quarter of 2015.

About Calithera

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera's lead product candidate, CB-839, is currently being evaluated in three Phase 1 clinical trials in solid and hematological cancers. Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit  www.calithera.com .

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," "poised" and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to Calithera's ability fund its clinical programs, and Calithera's receipt of clinical data from its clinical trials. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. The potential product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release. Such product candidates may not be beneficial to patients or successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera's stock price. Additional information concerning these and other risk factors affecting Calithera's business can be found in Calithera's Annual Report on Form 10-K for the year ended December 31, 2014, and other periodic filings with the Securities and Exchange Commission at www.sec.gov . These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Calithera disclaims any obligation to update these forward-looking statements to reflect future events or circumstances. 

Calithera Biosciences, Inc.
Selected Statements of Operations Financial Data
(in thousands)
(unaudited)
  Three Months Ended March 31,
  2015 2014
Operating expenses:    
Research and development  $ 5,630  $ 3,318
General and administrative  2,237  832
Total operating expenses  7,867  4,150
Loss from operations  (7,867)  (4,150)
Other income, net  9  1
Net loss  $ (7,858)  $ (4,149)
     
Calithera Biosciences, Inc.
Selected Balance Sheets Financial Data
(in thousands)
(unaudited)
 
  March 31, December 31,
  2015 2014
Balance Sheet Data:    
Cash, cash equivalents and investments  $ 94,275  $ 101,969
Working capital  86,789  99,742
Total assets  96,873  104,770
Total liabilities  3,769  4,404
Accumulated deficit  (59,712)  (51,854)
Total stockholders' equity  93,104  100,366

Jennifer McNealey 650-870-1071

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Nevada Expands Rural Youth Mental Health Access

Updated Category News Views 171

Nevada's Rural Mental Health Crisis When you're navigating the barren stretches of rural Nevada, the scenic views can be breathtaking. But for many families, finding basic services like mental health care is as challenging as striking water in the desert. Cartwheel Care has taken the bull by the horns with their latest initiative to bridge this glaring gap. Partnering...

Continue Reading
LongueVue Capital: Betting Big on Sports & Entertainment

Updated Category News Views 90

LongueVue Capital's Bold Move You don’t always hear about private equity firms diving head-first into the sports and entertainment sector, but LongueVue Capital (LVC) is doing just that. This New Orleans-based firm is shifting its gears and setting sights on founder-owned ventures crucial to these industries. They’re asking the key question: Why focus on just the...

Continue Reading
Teamsters Ratify Contract, Averting Waste Strike

Updated Category News Views 25

Big Win for Teamsters Local 350 You ever seen a strike averted by sheer willpower and unity? That’s what's happened here with the workers at South San Francisco Scavenger Company. These folks—drivers, mechanics, sorters, and utility workers—all banded together under the Teamsters Local 350 and showed management what's what by securing a contract they deserve. We're...

Continue Reading
AR Cards in Casino Gaming: A High-Stakes Revolution

Updated Category News Views 31

A New Breed of Casino Experience Walk into a casino today, and you might just enter a whole new reality. No, this isn’t a cheesy magician’s trick or a glitzy PR stunt—this is the real deal brought to you by augmented reality (AR) trading cards. Imagine the slots you love wrapped in a sci-fi movie where characters leap out, tap you on the shoulder, and call you by...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 95

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
FDA Changes Shake Up Medtech Inspections Landscape

Updated Category News Views 124

Inspecting the Changing FDA Landscape If you’ve been treating FDA inspections like a ride down memory lane, it's time for a wake-up call. What F. David Rothkopf plans to tell the medical device teams at the MEDevice Silicon Valley event is simple: the game has changed. The FDA’s Quality Management System Regulation (QMSR) that kicked in on February 2, 2026, isn’t...

Continue Reading
Sivers Semiconductors: Strategy Behind 2027 AGM Plans

Updated Category News Views 234

Setting the Stage for a Crucial Year Ah, the dance of corporate governance—an arena where maneuvering is an art. Sivers Semiconductors AB, a name that's becoming synonymous with innovation in the photonics and wireless solutions sector, is prepping for its 2027 Annual General Meeting. Ahead of this pivotal event, they're forming a Nomination Committee to shape future...

Continue Reading
Lululemon Faces Class Action over Alleged Missteps

Updated Category News Views 39

Trouble Brewing for Lululemon Y'ever get that gut feeling when something doesn't smell right? Well, Lululemon Athletica (NASDAQ: LULU) investors are probably feeling that now. A class action's kicking up dust over what some are saying was a downright bumpy ride. The brainiacs at Robbins LLP urge those who've lost bucks riding the LULU train to step forward ahead of the...

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 148

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 63

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading

Top 5 Most Recently Viewed Articles

Stellus Capital Achieves Milestone with 52-Week High Stock Surge

Updated Category News Views 254

Stellus Capital Achieves 52-Week High Stock Performance Stellus Capital Investment Corporation (NYSE: SCM) has recently marked a noteworthy milestone, with its stock soaring to a remarkable 52-week high of $14.7. This significant rise demonstrates the company’s robust growth trajectory and strategic maneuvers in the financial market. Stellus Capital has effectively...

Continue Reading
Key Market Movements Amid Global Economic Developments

Updated Category News Views 276

An Overview of Current Market Dynamics As we delve into the latest market trends, the dollar has recently experienced a notable decline, marking its lowest point of the year. This downturn is primarily attributed to the Bank of Japan's long-anticipated interest rate hike, which has shifted investor sentiments across the globe. Concurrently, the euro zone has shown...

Continue Reading
Zain Bahrain Claims Top Award for Outstanding Customer Engagement

Updated Category News Views 207

Zain Bahrain Claims Best-Connected Customer Experience Award Zain Bahrain, a major player in the telecommunications field, has recently been honored with the prestigious award for Best-Connected Customer Experience from IST Networks and Genesys. This remarkable recognition, awarded during LEAP, celebrates Zain Bahrain's remarkable journey in enhancing customer engagement...

Continue Reading
Insurance Crisis in America: Florida and California Impacted

Updated Category News Views 250

Alarming Insurance Trends in Florida and California The insurance landscape in certain parts of the United States is undergoing drastic changes. Recent analyses depict a troubling picture for homeowners in Florida and California, where reports show that a significant number of policyholders are being dropped by their insurance companies at an unprecedented rate. Florida...

Continue Reading
Axis Capital Achieves Record Stock High at $88.45

Updated Category News Views 134

Axis Capital's Remarkable Stock Performance In a stunning display of financial strength, Axis Capital Holdings Limited (NYSE: AXS) has achieved a groundbreaking stock price of $88.45, marking a historic milestone for the company. This surge reflects the robust growth that AXS has experienced over the past year, with a remarkable 59.47% increase noted in its stock...

Continue Reading